Lab Reference Library / Interleukin-6 (IL-6)
Advanced & Specialty
Interleukin-6 (IL-6)
IL-6 · Interleukin-6 · Pro-Inflammatory CytokineReference range, optimal functional medicine levels, and why IL-6 is the master cytokine of the acute-phase inflammatory response, how it drives CRP synthesis, promotes insulin resistance, accelerates bone loss, and why chronically elevated IL-6 is a central mediator of metabolic syndrome, cardiovascular disease, and accelerated aging.
Inflammatory CytokineMost Searched
Standard RangeBelow 7 pg/mL
FM OptimalBelow 3.5 pg/mL
ElevatedAbove 10 pg/mL
Unitspg/mL
← Back to Lab Reference Library
Category: Advanced & Specialty | Also known as: IL-6, Interleukin 6, B-Cell Stimulatory Factor-2 | Sample: Serum or plasma (fasting preferred; avoid recent acute illness)
1. What This Test Measures
Interleukin-6 (IL-6) is a pleiotropic cytokine produced by a wide range of cell types including immune cells (macrophages, monocytes, T and B lymphocytes), adipocytes, skeletal muscle, endothelial cells, and fibroblasts. It is one of the most extensively studied pro-inflammatory cytokines and serves as both a paracrine and endocrine signaling molecule with roles in acute inflammation, immune cell differentiation, hematopoiesis, metabolic regulation, and the acute phase response.
IL-6 is the primary driver of hepatic acute phase protein production: IL-6 binds IL-6 receptors on hepatocytes and upregulates synthesis of C-reactive protein (CRP), fibrinogen, serum amyloid A, ferritin, and other acute phase reactants. This is why CRP and IL-6 tend to track together: CRP is downstream of IL-6. Measuring IL-6 provides upstream information about the cytokine driving the CRP elevation.
In chronic low-grade inflammatory states, IL-6 is chronically elevated at lower levels than acute illness, and this chronic IL-6 signaling drives insulin resistance (IL-6 suppresses insulin receptor substrate-1 signaling), muscle catabolism, neuroinflammation, accelerated telomere shortening, and cardiovascular disease. This is the mechanism underlying the concept of inflammaging, the chronic subclinical inflammatory state associated with accelerated aging and metabolic disease.
2. Optimal Range and Clinical Thresholds
| IL-6 Level | Interpretation |
|---|---|
| Below 1.8 pg/mL | Optimal: minimal chronic inflammatory burden |
| 1.8 to 3.0 pg/mL | Borderline: evaluate for chronic inflammatory drivers; correlate with hs-CRP and clinical picture |
| 3.0 to 7.0 pg/mL | Elevated: significant chronic inflammation; comprehensive inflammatory driver evaluation warranted |
| 7.0 to 40 pg/mL | Markedly elevated: active inflammatory disease, obesity-driven inflammation, autoimmune flare, or chronic infection |
| Above 40 pg/mL | Severely elevated: suggests acute illness, severe autoimmune disease, or cytokine storm; urgent evaluation |
IL-6 is highly variable and sensitive to acute stimuli including recent exercise, minor infection, stress, and meal composition. Fasting collection after at least 12 hours, in the absence of acute illness, provides the most reliable chronic inflammatory baseline. Repeat measurement at 4 to 6 weeks is recommended before attributing persistent elevation to a chronic process.
3. Why IL-6 Drives Metabolic Disease
IL-6 is not merely a bystander in metabolic disease; it is a mechanistic driver. The following cascade explains how chronic IL-6 elevation connects visceral adiposity, insulin resistance, and cardiovascular disease:
- Visceral adipose tissue as IL-6 source: visceral fat releases 2 to 3 times more IL-6 than subcutaneous fat; this creates a portal vein IL-6 load that is delivered directly to the liver, stimulating hepatic CRP production, impaired insulin signaling, and altered lipid metabolism; this is why central obesity is more metabolically dangerous than peripheral obesity
- IL-6 and insulin resistance: IL-6 directly suppresses IRS-1 (insulin receptor substrate 1) signaling through SOCS3 (suppressor of cytokine signaling 3), reducing glucose transporter translocation in skeletal muscle and liver; this is the cytokine-driven pathway to insulin resistance that operates in parallel with the more commonly discussed lipotoxic pathway
- IL-6 and triglycerides: IL-6 upregulates hepatic VLDL production and reduces lipoprotein lipase activity in peripheral tissues, causing hypertriglyceridemia; this is one of the mechanisms by which chronic inflammation produces the typical dyslipidemia pattern of high triglycerides and low HDL
- IL-6 and atherosclerosis: IL-6 stimulates endothelial cell expression of adhesion molecules (ICAM-1, VCAM-1), monocyte recruitment, macrophage foam cell formation, and vascular smooth muscle proliferation; these are the cardinal steps of atherosclerotic plaque development and progression
4. Sources of Chronic IL-6 Elevation
- Visceral obesity: the most common cause of chronically elevated IL-6 in functional medicine patients; visceral adipocytes are pro-inflammatory endocrine organs; every 5 kg of excess visceral fat is estimated to raise baseline IL-6 by 15 to 20%
- Gut dysbiosis and intestinal permeability: LPS from gram-negative bacteria that translocates through a permeable gut barrier is the most potent macrophage activator for IL-6 production; gut-driven IL-6 elevation is a primary functional medicine driver of inflammaging
- Sleep deprivation: even one night of poor sleep raises IL-6 and TNF-alpha acutely; chronic sleep restriction maintains chronically elevated IL-6 that correlates with increased cardiovascular and metabolic risk
- Periodontal disease: gram-negative oral bacteria in diseased gum tissue chronically release LPS into the systemic circulation; oral health is a major and often overlooked driver of systemic IL-6 elevation
- Psychological stress: CRH and catecholamines released during stress directly stimulate macrophage IL-6 production; chronic psychological stress maintains chronically elevated IL-6 independent of body composition
- Sedentary behavior: skeletal muscle during contraction produces anti-inflammatory myokines (including IL-6 in a muscle-derived anti-inflammatory role) and reduces adipose tissue macrophage activation; physical inactivity removes this anti-inflammatory brake
5. How to Reduce IL-6
Adipose and Metabolic
- Visceral fat reduction: the most impactful intervention; even 5 to 10% weight loss significantly reduces IL-6; caloric deficit plus resistance training preferentially reduces visceral fat
- Resistance training (3 to 4 sessions weekly): builds metabolically active muscle that improves insulin sensitivity and reduces visceral adipocyte inflammatory output
- Mediterranean diet pattern: anti-inflammatory whole foods reduce adipose tissue inflammatory signaling; reduces IL-6 in multiple RCTs
- Intermittent fasting (16:8 protocol): reduces visceral fat and insulin-driven IL-6 production; also activates autophagy which reduces cellular inflammatory burden
Nutritional Interventions
- Omega-3 fatty acids (3 to 4g EPA and DHA daily): most evidence-based supplement for IL-6 reduction; competes with arachidonic acid for eicosanoid production; reduces macrophage IL-6 secretion; requires 8 to 12 weeks for full effect
- Curcumin (1,000 to 2,000mg daily with piperine): potent NF-kB inhibitor that directly reduces IL-6 gene transcription; multiple RCTs demonstrate IL-6 reduction in inflammatory conditions
- Resveratrol (500mg daily): SIRT1 activator with anti-IL-6 effects through NF-kB and AP-1 inhibition
- Magnesium glycinate (400 to 600mg daily): magnesium deficiency is associated with elevated IL-6; supplementation reduces IL-6 in deficient individuals
- Vitamin D (target 60 to 80 ng/mL): vitamin D receptor activation directly inhibits IL-6 production in macrophages and adipocytes
Lifestyle and Gut
- Sleep optimization (7 to 9 hours): sleep deprivation raises IL-6 within 24 hours; consistent adequate sleep is one of the fastest-acting IL-6 reducers
- Gut permeability reduction: assess and address zonulin, LPS, and sIgA; the LPS-macrophage-IL-6 cascade is a primary driver of metabolic inflammation
- Periodontal treatment: professional dental care and oral hygiene significantly reduces systemic LPS load and downstream IL-6
- Stress management: mindfulness, HRV biofeedback, and social connection reduce sympathetic activation-driven IL-6 production
- Cold thermogenesis (cold water immersion or cryotherapy): activates brown adipose tissue and reduces visceral adiposity-driven inflammation; emerging evidence for IL-6 modulation
6. Related Lab Tests
hs-CRPDownstream of IL-6; Inflammation Screen
→
LPSPrimary Driver of IL-6 from Gut
→
Fasting InsulinIL-6 Drives Insulin Resistance
→
Omega-3 IndexMost Evidence-Based IL-6 Reducer
→
FibrinogenAcute Phase Protein Co-regulated by IL-6
→
7. Clinical Perspective
Clinical Perspective
IL-6 is the link between belly fat and everything else I am treating in a metabolic syndrome patient. The visceral fat is not just sitting there looking bad; it is secreting IL-6 directly into the portal vein, and that IL-6 is driving the CRP elevation, the insulin resistance, the hypertriglyceridemia, and the endothelial dysfunction that will eventually produce cardiovascular events. When I see a patient with hs-CRP of 4.2, IL-6 of 8.6, fasting insulin of 22, and a HOMA-IR of 5.1, I know that the inflammatory and metabolic pictures are connected by a common upstream driver. That driver is visceral adiposity and its IL-6 output. Everything else follows from there, and every intervention I prescribe has to reduce visceral fat and IL-6 first before the downstream markers will improve. That is the mechanistic logic of the case.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
8. Frequently Asked Questions
What does elevated IL-6 mean?
Elevated IL-6 indicates active inflammatory signaling, either from acute illness (very high levels) or chronic low-grade inflammation (mildly to moderately elevated levels). The most common functional medicine causes of chronically elevated IL-6 are visceral obesity, gut dysbiosis with intestinal permeability, sleep deprivation, periodontal disease, and psychological stress. Chronic IL-6 elevation drives insulin resistance, cardiovascular disease, and accelerated aging.
How is IL-6 different from CRP?
CRP is produced by the liver in response to IL-6 signaling; it is downstream of IL-6. hs-CRP is a sensitive and widely available inflammation marker, but it does not tell you whether the inflammatory drive is coming from visceral fat, gut permeability, infection, or another source. IL-6 is upstream of CRP and provides more direct information about the cytokine driving the inflammatory response. Measuring both together provides more complete inflammatory characterization.
Why does visceral fat raise IL-6?
Visceral adipocytes (fat cells in and around abdominal organs) are more metabolically and immunologically active than subcutaneous fat. They release 2 to 3 times more IL-6 than subcutaneous adipocytes. This IL-6 is released into the portal circulation and delivered directly to the liver, where it stimulates CRP production, impairs insulin signaling, and alters lipid metabolism. This visceral fat IL-6 contribution explains why central obesity is disproportionately associated with metabolic disease compared to overall adiposity.
What supplements reduce IL-6?
The most evidence-based supplements for IL-6 reduction are omega-3 fatty acids (3 to 4g EPA and DHA daily; multiple RCTs demonstrate significant IL-6 reduction after 8 to 12 weeks), curcumin (1,000 to 2,000mg daily with piperine; direct NF-kB inhibition reduces IL-6 gene transcription), vitamin D (optimizing to 60 to 80 ng/mL; VDR activation inhibits macrophage IL-6 production), and magnesium (repleting deficiency reduces IL-6 in deficient individuals).
Does exercise affect IL-6?
Yes, in two distinct ways. Acutely, muscle contraction produces a large spike in muscle-derived IL-6 during exercise, but this acute IL-6 is anti-inflammatory in its function (it suppresses TNF-alpha and IL-1beta through IL-10 induction). Chronically, regular exercise reduces adipose tissue IL-6 production and systemic baseline IL-6 by reducing visceral fat and improving insulin sensitivity. Sedentary behavior, conversely, maintains chronically elevated baseline IL-6 from unchecked visceral adipose tissue activity.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Chronic IL-6 elevation is the cytokine signature of inflammaging. Its sources are identifiable and its reduction is measurable.
Schedule a consultation for comprehensive inflammatory marker evaluation including IL-6, hs-CRP, and metabolic drivers.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.